Literature DB >> 11517430

Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection.

L A Ryan1, J Zheng, M Brester, D Bohac, F Hahn, J Anderson, W Ratanasuwan, H E Gendelman, S Swindells.   

Abstract

The relationship between monocyte immune responses and cognitive impairment during progressive human immunodeficiency virus type 1 (HIV-1) infection was investigated in 28 subjects receiving highly active antiretroviral therapy. The mean+/-SEM CD4(+) T lymphocyte count and virus load for all patients were 237+/-41 cells/mm(3) and 77,091+/-195,372 HIV-1 RNA copies/mL, respectively. Levels of soluble tumor necrosis factor-alpha type II receptor (sTNF-RII) and soluble CD14 (sCD14) were measured in plasma by ELISA and were correlated with results from neuropsychological, magnetic resonance imaging, and magnetic resonance spectroscopy tests. Plasma sCD14 and sTNF-RII levels were elevated in subjects with cognitive impairment and in those with brain atrophy. Furthermore, both factors were correlated with spectroscopic choline:creatine ratios. These findings support the idea that peripheral immune responses are linked to cognitive dysfunction during advanced HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517430     DOI: 10.1086/323036

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  HIV-1 Infection Primes Macrophages Through STAT Signaling to Promote Enhanced Inflammation and Viral Replication.

Authors:  K Sofia Appelberg; Mark A Wallet; Jared P Taylor; Melanie N Cash; John W Sleasman; Maureen M Goodenow
Journal:  AIDS Res Hum Retroviruses       Date:  2017-04-12       Impact factor: 2.205

Review 2.  Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.

Authors:  Avanthi Raghavan; Dodie E Rimmelin; Kathleen V Fitch; Markella V Zanni
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

Review 3.  YKL-40: a candidate biomarker for simian immunodeficiency virus and human immunodeficiency virus encephalitis?

Authors:  Dennis L Kolson
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

4.  Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection.

Authors:  Tricia H Burdo; Allison Weiffenbach; Steven P Woods; Scott Letendre; Ronald J Ellis; Kenneth C Williams
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

5.  High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children.

Authors:  Sarah F Benki-Nugent; Ira Martopullo; Tony Laboso; Nancy Tamasha; Dalton C Wamalwa; Kenneth Tapia; Agnes Langat; Elizabeth Maleche-Obimbo; Christina M Marra; Paul Bangirana; Michael J Boivin; Grace C John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

Review 6.  HIV/neuroAIDS biomarkers.

Authors:  Pejman Rahimian; Johnny J He
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

Review 7.  Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.

Authors:  Anna C Hearps; Genevieve E Martin; Reena Rajasuriar; Suzanne M Crowe
Journal:  Curr HIV/AIDS Rep       Date:  2014-03       Impact factor: 5.071

Review 8.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities.

Authors:  Netanya G Sandler; Daniel C Douek
Journal:  Nat Rev Microbiol       Date:  2012-08-13       Impact factor: 60.633

9.  Differential transcriptional regulation by human immunodeficiency virus type 1 and gp120 in human astrocytes.

Authors:  D Galey; K Becker; N Haughey; A Kalehua; D Taub; J Woodward; M P Mattson; A Nath
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 10.  Monocyte/macrophages and their role in HIV neuropathogenesis.

Authors:  Tricia H Burdo; Andrew Lackner; Kenneth C Williams
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.